Medikaloka Hermina 관리

관리 기준 확인 2/4

Medikaloka Hermina CEO는 H. Hasmoro, Jan1991 에 임명되었습니다 의 임기는 33.83 년입니다. 는 IDR 1,010.47B 가치에 해당하는 회사 주식의 4.86% 직접 소유합니다. 1,010.47B. 경영진과 이사회의 평균 재임 기간은 각각 4.2 년과 6.8 년입니다.

주요 정보

H. Hasmoro

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	33.8yrs
CEO 소유권	4.9%
경영진 평균 재임 기간	4.2yrs
이사회 평균 재임 기간	6.8yrs

최근 관리 업데이트

Recent updates

CEO

H. Hasmoro (80 yo)

33.8yrs

테뉴어

Dr. H. Hasmoro, Sp An, KIC, MHA, MM, has been President Director of PT Medikaloka Hermina Tbk since 1991. Previously, Dr. Hasmoro served as Member of Presidential Specialist Team from 1987 to 2000.He join...

리더십 팀

이름	위치	테뉴어	보상	소유권
H. Hasmoro	President Director	33.8yrs	데이터 없음	4.86% IDR 1.0t
Yulisar Khiat	MD of Finance & Strategic Development and Director	less than a year	데이터 없음	13.02% IDR 2.7t
Tan Gunadi	MD of Operational & General Affairs and Director	less than a year	데이터 없음	데이터 없음
Binsar Simorangkir	MD of Medical and Compliance & Director	no data	데이터 없음	5.51% IDR 1.1t
Arie Wahyudi	Head of Licensing & Legal	no data	데이터 없음	데이터 없음
Muyi Hapsari	Head of Marketing	no data	데이터 없음	데이터 없음
Susi Setiawaty	MD of Human Capital	4.2yrs	데이터 없음	데이터 없음
Meijani Wibowo	Commissioner	no data	데이터 없음	2.21% IDR 460.0b
Hastiyudo Wibowo	Business Development	no data	데이터 없음	데이터 없음
Chatarina Sri Marsiyo	Head of Internal Audit	4.2yrs	데이터 없음	데이터 없음
Yuyun Gunaedi	Information Technology	no data	데이터 없음	데이터 없음

4.2yrs

평균 재임 기간

65.5yo

평균 연령

경험이 풍부한 관리: HEAL 의 관리팀은 경험 ( 4.2 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
H. Hasmoro	President Director	33.8yrs	데이터 없음	4.86% IDR 1.0t
Yulisar Khiat	MD of Finance & Strategic Development and Director	27.8yrs	데이터 없음	13.02% IDR 2.7t
Tan Gunadi	MD of Operational & General Affairs and Director	less than a year	데이터 없음	데이터 없음
Binsar Simorangkir	MD of Medical and Compliance & Director	26.8yrs	데이터 없음	5.51% IDR 1.1t
Susi Setiawaty	MD of Human Capital	less than a year	데이터 없음	데이터 없음
Meijani Wibowo	Commissioner	2.8yrs	데이터 없음	2.21% IDR 460.0b
Amit Varma	Independent Commissioner	4.8yrs	데이터 없음	데이터 없음
Alexander Rusli	Independent Commissioner	6.8yrs	데이터 없음	데이터 없음
Darwin Noerhadi	Commissioner	7.8yrs	데이터 없음	데이터 없음
Husen Sutakaria	Vice President Commissioner	6.8yrs	데이터 없음	2.85% IDR 591.1b
Paulus Gunawan	President Commissioner	7.8yrs	데이터 없음	데이터 없음
. Heridadi	Independent Commissioner	6.8yrs	데이터 없음	데이터 없음

6.8yrs

평균 재임 기간

66yo

평균 연령

경험이 풍부한 이사회: HEAL 의 이사회는 경험(평균 재직 기간 6.8 년)으로 간주됩니다.

Medikaloka Hermina 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Key Executive recently bought Rp4.5b worth of stock

Key Executive recently bought Rp109b worth of stock

President Director recently bought Rp5.0b worth of stock

President Director recently bought Rp8.3b worth of stock

President Director recently bought Rp308m worth of stock

Key Executive recently bought Rp687m worth of stock

Recent updates

Key Executive recently bought Rp4.5b worth of stock

Third quarter 2024 earnings released: EPS: Rp8.39 (vs Rp10.11 in 3Q 2023)

Key Executive recently bought Rp109b worth of stock

President Director recently bought Rp5.0b worth of stock

Second quarter 2024 earnings released: EPS: Rp10.25 (vs Rp6.45 in 2Q 2023)

President Director recently bought Rp8.3b worth of stock

Consensus EPS estimates increase by 13%

Investor sentiment improves as stock rises 17%

Now 20% overvalued

First quarter 2024 earnings released: EPS: Rp12.96 (vs Rp7.52 in 1Q 2023)

Full year 2023 earnings released: EPS: Rp30.16 (vs Rp20.64 in FY 2022)

New minor risk - Shareholder dilution

President Director recently bought Rp308m worth of stock

Key Executive recently bought Rp687m worth of stock

Third quarter 2023 earnings released: EPS: Rp10.12 (vs Rp5.61 in 3Q 2022)

Key Executive recently bought Rp12b worth of stock

Second quarter 2023 earnings released: EPS: Rp6.45 (vs Rp3.68 in 2Q 2022)

Price target increased to Rp2,170

Less than half of directors are independent

Consensus EPS estimates fall by 17%

PT Medikaloka Hermina Tbk Ordinary Shares to Be Deleted from OTC Equity

First quarter 2022 earnings: Revenues in line with analyst expectations

Price target increased to Rp1,427

Consensus EPS estimates fall by 15%

Less than half of directors are independent

Consensus forecasts updated

Full year 2021 earnings: EPS exceeds analyst expectations

PT Medikaloka Hermina Tbk (IDX:HEAL) announces an Equity Buyback for 80,000,000 shares, for IDR 116,000 million.

Third quarter 2021 earnings released: EPS Rp15.57 (vs Rp10.64 in 3Q 2020)

Price target increased to Rp1,255

Second quarter 2021 earnings released

Consensus EPS estimates increase to Rp50.58

Investor sentiment improved over the past week

Consensus EPS estimates increase to Rp222

Price target increased to Rp5,756

First quarter 2021 earnings released: EPS Rp95.79 (vs Rp24.16 in 1Q 2020)

Price target increased to Rp5,150

Consensus EPS estimates increase to Rp173

Price target increased to Rp4,959

Consensus EPS estimates increase to Rp160

New 90-day high: Rp4,200

New 90-day high: Rp4,000

New 90-day high: Rp3,930

Analysts update estimates

Price target raised to Rp4,368

New 90-day high: Rp3,450

Third quarter 2020 earnings released: EPS Rp53.13

First half earnings released

CEO

테뉴어

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령